Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-Acquired Pneumonia and Urinary Tract Infections

GlobeNewswire September 17, 2015

Paratek Pharmaceuticals, Inc. Announces Participation in Ladenburg Thalmann 2015 Healthcare Conference

GlobeNewswire September 2, 2015

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial and Operating Results

GlobeNewswire August 5, 2015

Paratek Pharmaceuticals to Present Data at ICAAC 2015

GlobeNewswire August 3, 2015

Paratek Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 5, 2015

GlobeNewswire July 28, 2015

Paratek Announces Termination of Tax Benefit Preservation Plan

GlobeNewswire July 24, 2015

Timothy Franson M.D. Joins Paratek's Board of Directors

GlobeNewswire July 22, 2015

Paratek Pharmaceuticals Opens New Corporate Headquarters in Boston

GlobeNewswire July 21, 2015

Paratek Pharmaceuticals Opens New Corporate Headquarters in Boston

GlobeNewswire July 21, 2015

Bion Could Help Nip Antibiotic Resistance at the Source

Accesswire July 20, 2015

Bion Could Help Nip Antibiotic Resistance at the Source

Accesswire July 20, 2015

Paratek Hires William Haskel as Senior Vice President, General Counsel and Corporate Secretary

GlobeNewswire July 1, 2015

Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections

GlobeNewswire June 23, 2015

Paratek Set to Join Russell 3000(R) and Russell Global Indexes

GlobeNewswire June 22, 2015

Paratek Pharmaceuticals to Present at Upcoming Banking Conferences

GlobeNewswire June 17, 2015

Paratek Pharmaceuticals Opens Philadelphia Office

GlobeNewswire June 11, 2015

Paratek Pharmaceuticals Strengthens Senior Leadership Team

GlobeNewswire June 3, 2015

Paratek Pharmaceuticals, Inc. Reports First Quarter 2015 Financial and Operating Results

GlobeNewswire May 15, 2015

LifeSci Capital Initiates Coverage of Paratek Pharmaceuticals

Accesswire May 13, 2015

Paratek Announces Closing of Common Stock Offering

GlobeNewswire May 5, 2015